Program Description

Raising capital is always challenging yet essential. Whether you’re advancing a promising new cancer therapy or developing a breakthrough medical device, securing significant funding is crucial to moving forward.

How do you decide whether to raise new funds, sell assets, cut expenses, or pursue an IPO? What options are realistic at different stages of the invention-to-commercialization process? How do inflection points influence these decisions, and how should the funds you raise be deployed?

CEOs and venture/PE investors from across the medTech and pharma sectors will share their experiences navigating these tough choices. The panel will discuss the importance of reaching key inflection points and risk-reduction milestones in the fundraising process, as well as different sources of capital at each stage of the development cycle. You will hear about the different perspectives of founders, existing investors, and new investors at each stage of development. You’ll also learn how the roles of management teams and boards evolve over the development and funding cycle.

Attendees will gain firsthand insights into how these leaders made critical funding decisions for their companies and investors—and what outcomes resulted from those choices.

Join us for an exceptional opportunity to hear from seasoned industry leaders as they share valuable strategies and critical insights into fundraising and navigating key inflection points in the development cycle.

James Biggins

President and CEO, Access Vascular

James is the Founder, President, and CEO of Access Vascular, Inc., a medical device company transforming vascular access through novel, hydrophilic biomaterials that reduce complications and improve patient outcomes. James’ background is in plastics engineering and an MBA from Babson College.

Thomas Busby

Partner, Mirus Capital Partners

Thom has nearly twenty years of experience in raising capital. He has spent the last decade of his career focused on the life sciences. An industry-dedicated investment banker and strategic advisor, Thom has advised dozens of growth-stage medical device, biotech, diagnostics, healthcare IT, and related service companies on exit planning and capital raising transactions.

David Constantine

CEO, Juniper Biomedical

David is the Co-Founder & CEO of Juniper Biomedical, a Massachusetts medtech company developing the future of precision bioelectronic medicine. With over 20 years of experience in MedTech across large multinational corporations and early-stage startups, David has led efforts in a variety of clinical and technical domains. He has co-founded several companies and raised capital from angel investors, family offices, and venture capital firms in the US and abroad.